News

  1. Fact Sheet for Healthcare Professionals

    Downloadable fact sheet answering the most common question TheSocialMedwork asked by healthcare providers.

    doctor ok sign

    Read more »
  2. I love someone who is rare

    In recognition of Rare Disease Day, our colleague, Sera, shares her story of her dad's fight with Multiple System Atrophy (MSA). 

    rare patient with heart

    Read more »
  3. Kalydeco (ivacaftor) now approved in Canada for kids aged 1-2

    Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

    toddler in park with bubles

    Read more »
  4. Prescriber: TheSocialMedwork, providing access to overseas medicines

    Prescriber

    Read more »
  5. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Read more »
  6. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  7. Teresa's story: how ALS changed my life

    Teresa's husband was diagnosed with ALS. She spent 11 years as his caregiver and discusses her experiences.

    teresa: caregiver story

    Read more »
  8. New study supports FDA's decision to approve Copiktra (duvelisib)

    woman smiling sunny

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    Read more »
  9. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    old bench

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    Read more »
  10. Onpattro (patisiran): the first RNAi therapeutic approved in the European Union

    Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

    EU approval OK hand gesture

    Read more »
Posts loader